Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Prostate and bladder highlights at ESMO 2021

Joaquim Bellmunt, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, discusses key updates from prostate and bladder cancer at the European Society for Medical Oncology (ESMO) 2021 congress. In prostate cancer, Dr Bellmunt discusses the practice-changing PEACE-1 study (NCT01957436) which reported overall survival results highlighting improved responses with the addition of abiraterone in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) as well as the results from the STAMPEDE trial (NCT00268476). In bladder cancer, Dr Bellmunt highlights the results from the Phase III VESPER (NCT01812369) study as well as the findings from the Phase II trial of pembrolizumab in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC). In addition, the first results from the NORSE study (NCT03473743), a Phase II trial evaluating erdafitinib, an FGFR inhibitor, or erdafitinib plus cetrelimab in patients with metastatic or locally advanced urothelial carcinoma and FGFR alterations are discussed. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.